Dr. Bob Li
Multinational drugmaker AstraZeneca has named Dr. Bob Li, a top Asian leader from the New York-based Memorial Sloan Kettering Cancer Center, to the post of global head of medical affairs involving oncology, according to an announcement at the company’s website.
At MSK, Li was physician ambassador to China and Asia-Pacific, as well as vice president for global research affairs. The Shanghai-born, Australian national has been a high-profile advocate for expanding access to clinical trials as a means to lower cancer fatality rates.
“The future of oncology is not academic cancer centers, but cancer networks,” Li said in a statement. “It’s about leveraging collaboration and technology to improve access for the more than 90% of patients in diverse global communities who miss out on clinical trials and precision oncology.”
Li, 42, has been a regular speaker for the past five years at Forbes China Healthcare Summits organized by Forbes China, the Chinese-language edition of Forbes. In his new position, he will be based in the Washington, D.C. area.
Li also has been a senior fellow on global public health at the Asia Society Policy Institute’s Center for China Analysis and a co-founder of that institute’s Cure4Cancer Initiative. Forbes China is a strategic partner of Cure4Cancer.
“Fundamentally Wrong”: Less Than 5% Of Cancer Patients Get Access To Clinical Trials
Gaby Golf Girl Might Have Rx For Cancer Breakthroughs
